HC Wainwright Has Optimistic View of Vericel FY2026 Earnings

Vericel Corporation (NASDAQ:VCEL) – Investment analysts at HC Wainwright lifted their FY2026 EPS estimates for Vericel in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.79 for the year, up from their prior forecast of $0.45. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for Vericel’s Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.15 EPS and FY2027 earnings at $0.89 EPS.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The business had revenue of $85.37 million during the quarter, compared to analyst estimates of $77.95 million. During the same period in the previous year, the business posted $0.10 earnings per share. Vericel’s revenue for the quarter was up 26.5% on a year-over-year basis.

VCEL has been the subject of a number of other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. TD Cowen upped their target price on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen raised Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Truist Financial increased their target price on Vericel from $52.00 to $65.00 and gave the company a “buy” rating in a research note on Friday. Finally, Canaccord Genuity Group set a $60.00 price target on Vericel in a research report on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $60.80.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $58.39 on Tuesday. The company’s fifty day moving average price is $41.36 and its 200-day moving average price is $39.00. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of 91.24 and a beta of 1.08. Vericel has a one year low of $28.95 and a one year high of $59.48.

Institutional Investors Weigh In On Vericel

A number of large investors have recently added to or reduced their stakes in VCEL. BlackRock Inc. purchased a new position in shares of Vericel during the second quarter valued at approximately $360,023,000. William Blair Investment Management LLC bought a new position in shares of Vericel in the 2nd quarter worth about $88,662,000. Aberdeen Group plc lifted its position in Vericel by 204.7% during the 3rd quarter. Aberdeen Group plc now owns 2,164,250 shares of the biotechnology company’s stock valued at $86,873,000 after acquiring an additional 1,454,012 shares during the period. Bank of America Corp DE purchased a new position in Vericel during the 2nd quarter valued at about $45,210,000. Finally, TimesSquare Capital Management LLC purchased a new position in Vericel during the 2nd quarter valued at about $24,463,000.

Insider Activity at Vericel

In other Vericel news, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total value of $778,800.00. Following the completion of the sale, the insider directly owned 1,990 shares of the company’s stock, valued at $103,320.80. The trade was a 88.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert L. Md Zerbe sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $52.23, for a total value of $156,690.00. Following the transaction, the director owned 32,995 shares in the company, valued at approximately $1,723,328.85. The trade was a 8.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 22,000 shares of company stock valued at $1,128,340. Insiders own 7.60% of the company’s stock.

About Vericel

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States.

Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

The company traces its roots to Aastrom Biosciences and adopted the Vericel name in 2014.